join us at ispor vienna - iqvia · qi ispor vienna invite orb1679_layout 1 17/10/2016 06:32 page 2...

Explore “Novel approaches to evidence-drivendesign and study sample-frame validation” in our symposium

Meet the largest expert community in real-world evidence (RWE)Discover the findings from our latest research

Join us at ISPOR Vienna29 October–2 November 2016

Real-World Insights

QI ISPOR Vienna Invite ORB1679_Layout 1 17/10/2016 06:32

The new QuintilesIMS is proud to bring you our combined scientific and disease areaexpertise, technology and operational capabilities.

But what is really new is that we are connecting these in ways that haven’t been seen before. We invite you to join us at ISPOR to discover the exciting opportunities enabled by our real-world insights, asdemonstrated through a range of compelling research presentations. Details of our full program can be found in this brochure on pages 5–10.

Experts from the global QuintilesIMS Real-World Evidence Solutions and Consulting teams will be on hand throughout the event at our Stand (609–612).

We look forward to seeing you in Vienna!

Welcome to the QuintilesIMS Program at ISPOR Vienna

Podium Presentation 31 October, 1 1 :30–11:45The impact of dynamic transmission modelling on theestimated cost-effectiveness of treatment for chronicHepatitis C in the United Kingdom

Workshop 1 November, 08:45–09:45Let’s go fly a kite – managing the winds of change in real-world evidence studies

Educational Symposium 1 November, 12:30–13:30Novel approaches to evidence-driven design and studysample-frame validation

ISPOR Forum 1 November, 17:45–18:45New issues & emerging trends in HEOR: Revising theISPOR Code of Ethics

See pages 5–10 for further details

Our experts will be running personal demos of two leading-edge QuintilesIMS market access and RWI solutions during ISPOR.

HTA Accelerator: An integrated solution providing instant insights into payer decision making based on HTA reports of 100+ agencies in 32 countries across different therapeutic areas.

E360™: A powerful suite of RWI applications that can help you answer even the most challenging questions in a standardized, intuitive way.

Schedule your individual demo(s), either at our Stand or by emailing [email protected] INSIGHTS

R

Live Sessions with QuintilesIMS

Book a demo at ISPOR

2 | QuintilesIMS at ISPOR Vienna, 2016


“Novel approaches to evidence-driven design and study sample-frame validation”

• Over the last two decades, pharma has made significant progress in improving development timelines and better

managing pipeline value attrition. But there is still more that can be done.

• Real-world data (RWD) has begun to complement classical methods for clinical development which revolved around

understanding clinical outcomes from published studies and KOL insights.

• During this symposium, we will explore and demonstrate through case studies the value of RWD in driving efficiency

directly and indirectly, as well as improving the effectiveness of studies.

• Our panel of senior experts from pharma and QuintilesIMS will showcase how RWD evidence-driven design

improves clinical development and late phase studies from both a CRO and industry perspective, and the benefits of

better data access for epidemiology.

Symposium Tuesday, 1 November

Introduction: The case of RWD transforming R&D 12:30–12:35 Jacco Keja, PhD, (Chair) Senior Principal, RWE Solutions, QuintilesIMS, UK; Lecturer, Erasmus University, The Netherlands, IBMG

Using RWD to improve clinical trial performance 12:35–12:50 Natalia Balko, MBA, Principal, RWE Solutions, QuintilesIMS, UK

Innovation in RWD access & analysis for pharmaceutical organizations 12:50–13:05 Andrew Bate, PhD, Senior Director, Epidemiology Group Lead, Analytics & Worldwide Safety, Pfizer Ltd, UK

Using RWD to inform endpoint strategy for clinical trials 13:05–13:20Solomon Iyasu, MD, MPh, VP, Pharmacoepidemiology, Center for Observational Real-World Evidence, Merck & Co, USA

Moderated Q&A 13:20–13:30 Jacco Keja, PhD (Chair)


Symposium Agenda


Jacco Keja, PhD (Chair)Dr. Jacco Keja is Senior Principal, RWE Solutions at QuintilesIMS in the UK, drawing on deep expertise in globalmarket access, operational and strategic pricing, and health economics and outcomes research. His backgroundincludes four years as global head of pricing, reimbursement, health outcomes and market access consultingservices at a large clinical research organization and more than 13 years experience in the pharmaceutical industry,including senior-level international and global roles in strategic marketing, pricing and reimbursement and healtheconomics. Jacco is also lecturer at the Institute of Health Policy & Management at Erasmus University, Rotterdam.

Natalia Balko, MBANatalia Balko is Principal, RWE Solutions at QuintilesIMS in the UK, driving strategic initiatives to develop new RWEsolutions for the company globally through acquisitions and partnerships. This includes building relationships withnew partners and collaborating to deliver innovative RWE services to clients. Natalia has expertise in oncology andmolecular diagnostics and study methods combining retrospective and prospective data. Her background includespricing and market access consulting with the IMS Consulting Group and corporate strategic and businessdevelopment in an oncology-focused biotechnology company.

Andrew Bate, PhDDr. Andrew Bate is Senior Director, Epidemiology Group Lead, Analytics & Worldwide Safety, at Pfizer in the UK,overseeing the provision of methodological and analytic expertise for drug development and safety evaluationactivities. In 2011, he was appointed co-lead of the Data and Analytics work stream for developing an enterprise-wide strategy for Pfizer's use of RWD that resulted in the establishment of an RWD & Analytics function. Andrewpreviously spent over 12 years at the Uppsala Monitoring Centre, WHO Collaborating Centre for International DrugMonitoring, heading the research function of the Institute from 2003. With a research focus on methods and toolsfor analyzing RWD to support drug development, Andrew has published more than 50 papers and contributed tovarious international and national initiatives in medicinal safety, with CIOMS, OMOP and the FDA Science BoardSubcommittee on Pharmacovigilance. He holds Executive and Board positions at ISOP and ISPE respectively and isan Adjunct Associate Professor in Clinical Pharmacology at NYU School of Medicine, USA and affiliate faculty at theNYU Center for Health Informatics and Bioinformatics.

Solomon Iyasu, MD, MPhDr. Solomon Iyasu is VP, Pharmacoepidemiology, Center for Observational RWE, at Merck in the USA, leading adepartment responsible for PASS/PAER studies and RWD analytics to characterize disease epidemiology andinform early development, clinical trial design and endpoint strategy. In his prior role as Director of OPE in the FDA’sOffice of Surveillance and Evaluation, Center for Drug Evaluation & Research, he led the Divisions ofPharmacovigilance & Epidemiology, CDER’s participation in the Sentinel Surveillance Program, and all related drugsafety epidemiology research. Solomon was previously Director, Division of Epidemiology at OSE and is largelycredited with building the regulatory epidemiology program and vastly increasing the role of epidemiological datain regulatory decision making. During his 13 years with the FDA he held leadership positions on various committeesand workgroups including CDER’s Drug Safety Oversight Board. Solomon also spent over 10 years as Lead MedicalEpidemiologist, Centers for Disease Control and Prevention, conducting perinatal and pediatric epidemiologystudies to evaluate pregnancy and infant outcomes. He has published numerous scientific research papers andbook chapters.


Symposium Panel



MO3THE IMPACT OF DYNAMIC TRANSMISSION MODELLING ON THE ESTIMATEDCOST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HEPATITIS C IN THEUNITED KINGDOM

Madin-Warburton M, Pitcher A, Martin N

PodiumPresentation

PRM18A18 PAYER REQUIREMENTS IN THE TREATMENT OF CHRONIC HEART FAILURE Bergenheim K, Hellsten Kronander A,

Lauks S, van Engen APosterPresentation

PRM56B18

VIABILITY OF USING ELECTRONIC MEDICAL RECORDS FROM EUROPEANCOUNTRIES AS DATA IN NOVELTY (A NOVEL OBSERVATIONAL LONGITUDINALSTUDY OF PATIENTS WITH ASTHMA AND/OR COPD)

Wang X, Sveréus A, Rennard S, Hiller J, Wong D, Nasuti P, Jenner H, McKenney A, Gerhardsson de Verdier M

PosterPresentation

PRM81C5

IMPLICATIONS OF INTRODUCING PATIENT HETEROGENEITY IN COSTEFFECTIVENESS MODELING Foos V, McEwan P, Lamotte M Poster

Presentation

PRM85C9

REPLACING INPUT PROBABILITY DISTRIBUTIONS WITH MEAN VALUES CAN BIASSIMULATION OUTPUT: AN ILLUSTRATION USING THE CORE DIABETES MODEL McEwan P, Foos V, Lamotte M Poster

Presentation

PRM92C16

AUTOMATIC EXTRACTION AND CLASSIFICATION OF PATIENTS’ SMOKING STATUS FROM FREE TEXT USING NATURAL LANGUAGE PROCESSING

Caccamisi A, Jörgensen L, Dalianis H, Rosenlund M

PosterPresentation

PRM115D1

THREE-MONTHLY LONG-ACTING FORMULATION OF PALIPERIDONE PALMITATE IS A DOMINANT TREATMENT OPTION, COST SAVING WHILE ADDING QALYS,COMPARED TO THE ONE-MONTHLY FORMULATION IN THE TREATMENT OFSCHIZOPHRENIA IN FRANCE

Arteaga Duarte C, Colin X, De Moor R, Guillon P, van Gils CW

PosterPresentation

PRM120D6

DO HEALTH TECHNOLOGY AGENCIES ACCEPT METHODS FOR DEALING WITHTREATMENT SWITCHING AND IMMATURE OS DATA?

Zhang Y, Wright J, Luke S, Ryan J, van Engen A

PosterPresentation

PRM131D17

METHODOLOGICAL REVIEW OF SURVIVAL MODELS: APPLICATION TO APERSISTENCE ANALYSIS BASED ON LONG ACTING PARENTERAL ANTIPSYCHOTIC IN RETAIL PHARMACIES IN FRANCE

Harmand S, El Mouaddin N PosterPresentation

PRM134D20

STATISTICAL MODELS TO PREDICT INDICATION OF RESPIRATORY PATIENTSBETWEEN ASTHMA AND COPD

Ilgin Y, Staus A, Chauvin F, Leheyda N, Wolk A, Witte M,Subramani S

PosterPresentation

PRM198F8 EXTRACTING DOSAGE PER DAY FROM FREE-TEXT MEDICATION PRESCRIPTIONS

Törnblom M, Bergman G, Jørgensen L, Fackle-Fornius E,Rosenlund M

PosterPresentation

PRM207F17

HOW TO MAXIMISE THE VALUE AND PAYERS’ ACCEPTANCE OF SINGLE ARMTRIAL DATA IN ONCOLOGY?

Hoyle C, Wright J, Ede J, van Engen A, Ryan J

PosterPresentation

PRM216F26

RATIONALE AND DESIGN OF A MULTI-CENTER SURVEY TO EVALUATEPRODUCTIVITY LOSSES AND INDIRECT COSTS AFTER CARDIOVASCULAREVENTS IN EUROPE

Gerlier L, Sidelnikov E, Kutikova L,Lamotte M, Annemans L

PosterPresentation

PIN5H12

TRANSLATION OF THE UK PAEDIATRIC INFLUENZA PRIMARY SCHOOLVACCINATION PROGRAMME TO 13 EUROPEAN COUNTRIES USING A DYNAMICTRANSMISSION MODEL

Gerlier L, Hackett J, Lawson RW, Dos Santos Mendes S, Eichner M

PosterPresentation

PIN80J12

UTILISATION AND DOSAGE PATTERNS OF INTRAVENOUS ECHINOCANDINS FORTREATMENT OF INVASIVE FUNGAL INFECTIONS WITHIN HOSPITALS IN ENGLAND

Ahir HB, McCann E, Robertson S,Patel S, Yu E, Tham R

PosterPresentation

PND9K5

GLATIRAMER ACETATE (GA) RESULTS IN SIGNIFICANT REDUCTIONS INANNUALIZED RELAPSE RATE (ARR) AND PROTECTIVE EFFECT ON DISABILITYPROGRESSION: RESULTS FROM A NETWORK META-ANALYSIS

Ivanescu C, Wu Y, Kool-Houweling LM,van Engen A

PosterPresentation

PND12K8

A RETROSPECTIVE NON-INTERVENTIONAL STUDY AMONG PATIENTS WITHRELAPSING MULTIPLE SCLEROSIS SWITCHING TO FINGOLIMOD OR TO OTHERDISEASE MODIFYING THERAPIES

Medin J, Haddad P, Ricart J, Lara N,Pedros M, Bizouard G, Loefroth E

PosterPresentation

Code + Location Topic Presenters Type

QuintilesIMS Activities 31 OctoberMONDAY 31


PND30K26 PRESCRIPTION PATTERNS AND COSTS OF MIGRAINE THERAPY IN GERMANY Voss F, Dombrowski S, Jacob L,

Kostev KPosterPresentation

PND37K32

THE COST-EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FUMARATEVERSUS GLATIRAMER ACETATE FOR THE TREATMENT OF RELAPSING-REMITTINGMULTIPLE SCLEROSIS IN THE CHILEAN NATIONAL HEALTH FUND (FONASA)

Noda C, de Anda JA, Anaya P, Serafini P, Machado M

PosterPresentation

PND40K35

THE COST-EFFECTIVENESS OF DELAYED RELEASE DIMETHYL FUMARATEVERSUS GLATIRAMER ACETATE FOR THE TREATMENT OF RELAPSING-REMITTINGMULTIPLE SCLEROSIS IN THE MEXICAN SOCIAL SECURITY INSTITUTE (IMSS)

de Anda JA, Noda C, Anaya P, Azamar A, Machado M, Serafini P

PosterPresentation

PND50L8

GLATIRAMER ACETATE (GA) IS COST-EFFECTIVE COMPARED TO INTERFERONSAND BEST SUPPORTIVE CARE (BSC) FOR RELAPSING REMITTING MULTIPLESCLEROSIS (RRMS) IN THE UK

Maervoet J, Ivanescu C, Wu Y, van Engen A

PosterPresentation

PND66L24

WORK PRODUCTIVITY AND USE OF DISEASE-MODIFYING THERAPIES INMULTIPLE SCLEROSIS: RESULTS FROM A PATIENT SURVEY ACCESSED THROUGHSOCIAL MEDIA

Medin J, Ghodge B, Bonzani I, Korn JR, Olson M, Risson V

PosterPresentation

PND77L35

PRESCRIPTION PATTERNS AND DRUGS COSTS IN PATIENTS WITH DEMENTIA - A RETROSPECTIVE DATABASE ANALYSIS

Beck K, Jacob L, Booker A, Bohlken J, Kostev K

PosterPresentation

PHP16A16

BIOSIMILARS: MARKET ACCESS AND MARKET PENETRATION – A COMPARISONOF FRANCE AND GERMANY Freiberg M, Schwarz R, Khoury C Poster

Presentation

PHP24A24

ASSESSING THE AVERAGE PRICE LEVEL OF GENERICS IN GREECE AND OTHERCOMPARABLE EUROPEAN COUNTRIES RELATIVE TO THEIR VOLUME MARKETSHARE

Papadopoulos C, Lolos D, Ollandezos M

PosterPresentation

PHP33A33 AN ASSESSMENT OF BIOSIMILARS’ BEHAVIOUR IN THE EU-5 COUNTRIES Planellas L, Solozabal M,

Manganelli A, Rebollo P, Puig-Junoy JPosterPresentation

PHP37A37

THE IMPACT OF REGIONAL LEGISLATIVE MEASURES ON THE PRESCRIPTION OFOFF-PATENT MEDICINES Tettamanti A, Urbinati D, Tucci C Poster

Presentation

PHP38A38

COMPARISON OF BIOSIMILAR GUIDELINE AND REAL CONSUMPTION AMONGITALIAN REGIONS Tettamanti A, Urbinati D, Tucci C Poster

Presentation

PHP68B30 TIME TRENDS IN SEQUENCE OF DRUG LAUNCH ACROSS EU5 Gubbels L, Dekkers R, Nijhuis T Poster

Presentation

PHP70B32 REGIONAL TIME TO MARKET OF INNOVATIVE DRUGS IN ITALY Mantuano M, Daniel F, Urbinati D Poster

Presentation

PHP108C31

SHORT AND LONG TERM COSTS ASSOCIATED WITH DIFFERENTCARDIOVASCULAR EVENTS IN BELGIUM

Caekelbergh K, Chevalier P, Lamotte M, Kutikova L, Schutyser E,Annemans L

PosterPresentation

PHP162E8 MARKET UPTAKE OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN GERMANY

Batscheider A, Dannemann S, Gaba D, Paulus G, Antoni B, Stoecker P, Greese B, Greiner R

PosterPresentation

PHP164E10 BIOSIMILARS AND REFERENCE PRICE GROUPS IN GERMANY Eheberg D, Pointner J, Antoni B,

Gossmann JA, Batscheider A PosterPresentation

PHP165E11

EXTRA BUDGETARY REIMBURSEMENT OPTIONS FOR INNOVATIONS IN THEGERMAN HOSPITAL SECTOR

Freiberg M, Schwarz R, Schalk E, Kraft T

PosterPresentation

PHP170E16 MARKET ACCESS PATHWAYS FOR DRUGS WITH EMA CONDITIONAL APPROVAL Lie X, Kreeftmeijer J, Bossers N,

Haigh JPosterPresentation



QuintilesIMS Activities 31 OctoberMONDAY 31


7

PHP174E20

VARIATIONS IN STAKEHOLDER PREFERENCES BETWEEN INNOVATIVE PRICINGAGREEMENT TYPES ACROSS THE EU5 Edwards G, Staufer A, Dunlop W Poster

Presentation

PHP176E22

QUANTIFICATION OF PATIENT PREFERENCE ANALYSIS: WEARING THE FEDERALJOINT COMMITTEE LENS TO ASSESS EVIDENCE Gaba D, Eheberg D, Bonduelle D Poster

Presentation

PHP206F13

IS THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) SET UP FORSUCCESS? A COMPARISON BETWEEN ICER AND EX-U.S. HTA AGENCIES

Skolas K, Pruefert A, Yee S, van Engen A

PosterPresentation

PHP219F25

ITALIAN ELECTRONIC HEALTH RECORDS MAPPING: IS CLINICAL DATACOLLECTION GETTING IN LINE WITH THE REAL WORLD EVIDENCE ERA?

Avitabile A, Caputo A, Gilardelli G,Golotta C, La Grasta L, Heiman F,Porrello N

PosterPresentation

PHP266G33

NICE COLLATERAL EFFECT: WHAT IS THE INFLUENCE OF NICE ON OTHER HTABODIES?

Wijnands T, Kreeftmeijer J, Kooreman PJ, Wagner P, van Engen A

PosterPresentation

PHP309H38

“BEST SUPPORTIVE CARE” OR “THERAPY ACCORDING TO PHYSICIAN'S CHOICE”AS APPROPRIATE COMPARATOR FOR GERMAN HTA DOSSIERS – ANUNDERESTIMATED CHANCE OR RISK FOR THE BENEFIT ASSESSMENT?

Eheberg D, Dannemann S, Jakovac M, Bonduelle D

PosterPresentation

PHP311I2

IMPACT OF POST-INSCRIPTION STUDIES ON REASSESSMENT IN FRANCE: A CASE STUDY ON ORPHAN DRUGS Jubert H, Ouali I, Kolahi C Poster

Presentation

PHP378J31

GETTING MEDICAL INNOVATION TO PATIENTS IN DEVELOPING COUNTRIES - A SYSTEMIC APPROACH TO SETTING PRICE AND ACCESS Shankar R Poster

Presentation

PGI1K6

UNSPECIFIED INTESTINAL MALABSORPTION ASSOCIATED WITH ANGIOTENSINRECEPTOR BLOCKER THERAPY: RESULTS FROM A NATIONWIDE, POPULATION-BASED STUDY IN ITALY AND GERMANY

Ripellino C, Cataldo N, Scarpignato C PosterPresentation

PGI13K18

HOSPITALIZATION COSTS ASSOCIATED WITH CROHN'S DISEASE ANDULCERATIVE COLITIS IN BELGIUM Chevalier P, Lamotte M Poster

Presentation

PGI32K37 BIOLOGICS USE IN CROHN’S DISEASE IN FRANCE Gaudry J, Morand F, Willemin L,

Lee XY, Lelli FPosterPresentation

Hall D (L2) NOVEL APPROACHES TO EVIDENCE-DRIVEN DESIGN AND STUDY-SAMPLEFRAME VALIDATION Keja J, Balko N, Bate A, Iyasu S Educational

Symposium

W11Hall D (L2)

LET’S GO FLY A KITE – MANAGING THE WINDS OF CHANGE IN REAL-WORLDEVIDENCE STUDIES Bourke A, Bate A, Hall GC Workshop

F8Hall E1 (L0)

NEW ISSUES & EMERGING TRENDS IN HEOR: REVISING THE ISPOR CODE OFETHICS

Willke RJ, Santos J, Drummond M,Parmenter L, Sandhu G Forum

PMH3A3

RHEUMATOID ARTHRITIS IS ASSOCIATED WITH AN INCREASED RISK OFDEPRESSION IN ELDERLY PATIENTS IN GERMANY

Drosselmeyer J, Booker A, Jacob L,Kostev K

PosterPresentation

PMH20A20

IMPACT OF COMORBIDITIES ON THE COST OF DEPRESSION DRUG THERAPY INGENERAL PRACTICES IN GERMANY Jacob L, Ehlken B, Kostev K Poster

Presentation

PMH28A28

THREE-MONTHLY LONG-ACTING FORMULATION OF PALIPERIDONE PALMITATE IS A DOMINANT TREATMENT OPTION, COST SAVING WHILE ADDING QALYS,COMPARED TO THE ONE-MONTHLY FORMULATION IN THE TREATMENT OFSCHIZOPHRENIA IN BELGIUM: A COST-UTILITY STUDY

De Moor R, Malfait B, Tedouri F, De Vos C, van Gils C

PosterPresentation



QuintilesIMS Activities 31 October & 1 NovemberTU

ESDAY 1


8 | QuintilesIMS at ISPOR, Vienna, 2016


PMH47B9

TREATMENT INDICATIONS FOR ANTIDEPRESSANTS PRESCRIBED IN PRIMARYCARE IN FRANCE, 2006-2015

Schwalm M, Miotti H, Hellard C,Bounit L, Trehony J, Jouaville SL

PosterPresentation

PMS73D8

OLOKIZUMAB TREATMENT OF BOTH WESTERN AND ASIAN PATIENTS WITHRHEUMATOID ARTHRITIS WHO HAVE FAILED ANTI-TNF TREATMENT RESULTS INSUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES

Genovese MC, Durez P, Fleischmann R, Tanaka Y, Furst DE,Yamanaka H, Vasyutin I, Kaviarasu T,Korneva E, Koloda D, Takeuchi T

PosterPresentation

PRS18E12

COSTS OF PERENNIAL ALLERGIC RHINITIS AND ASTHMA INCREASE WITH LEVELOF SEVERITY AND LEVEL OF DISEASE CONTROL

Belhassen M, Demoly P, Bloch-Morot E, de Pouvourville G,Ginoux M Chartier A, Laforest L,Serup-Hansen N, Toussi M, van Ganse E

PosterPresentation

PRS72F27

HEALTH TECHNOLOGY ASSESSMENTS OF LAMA/LABA COMBINATIONPRODUCTS Lindner L, Ede J, van Engen A, Lai L Poster

Presentation

PSS4F31

A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF INTRAVITREALAFLIBERCEPT INJECTION VERSUS OTHER TREATMENTS FOR MACULAR EDEMASECONDARY TO CENTRAL RETINAL VEIN OCCLUSION

Krivasi T, Guillermin A, Muston D,Lloyd A

PosterPresentation

PSS12G1

PREDICTING RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORTREATMENT USING ELECTRONIC MEDICAL RECORD DATA IN EYES WITHNEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Andrews C, D'Souza K, Lacey S, Rigg J, Pitcher A, Milnes F

PosterPresentation

PSS21G10

DOSE INCREASE BEYOND LABELLED DOSE OF BIOLOGIC TREATMENTS INMODERATE TO SEVERE PSORIASIS IS ASSOCIATED WITH INCREMENTALPHARMACY COSTS: A REAL-WORLD STUDY IN THE UK

Hermans R, Tian H, Gilloteau I,Whitehead J, Buysse B

PosterPresentation

PSY2H20

THE HECTOR STUDY: HEALTH ECONOMICS STUDY OF CODEINE AND TRAMADOLNON-RESPONDERS – A SUB POPULATION ANALYSIS

Pockett RD, O'Leary CJ, Winfield TG,Anderson P, Nasser A, Ansell D

PosterPresentation

PSY20H38

CHARACTERISTICS, RESOURCES UTILIZATION AND SAFETY PROFILE OFPATIENTS WITH ACUTE PAIN: A EUROPEAN REAL WORLD EVIDENCE STUDY

Katz P, Pegoraro V, Heiman F,Liedgens H

PosterPresentation

PSY42I22

THE GOOD THE BAD AND THE NON-QUANTIFIABLE – A COMPARISON OFREBATES ON ORPHAN DRUGS VERSUS NON-ORPHAN DRUGS IN GERMANY Wijnands T, Schuchardt M, Nijhuis T Poster

Presentation

PSY45I25

INTRAVENOUS (IV) ADMNISTRATION OF MORPHINE FOR MODERATE-TO-SEVEREACUTE PAIN IN THE EMERGENCY ROOM (ER) SETTING INFLICTS A SUBSTANTIALECONOMIC BURDEN IN THE EU5

DiDonato K, Palmer PP, Morris TE,Walker J, Casamayor M,Hennebert M

PosterPresentation

PSY112K17

NEUROPATHIC PAIN IN CHRONIC LOW BACK PAIN: A PATIENT-CENTEREDAPPROACH TO MEASURING OUTCOMES

Hwang S, English M, Evans CJ, Wells T, Ryan A, Crawford B, van Nooten F

PosterPresentation

PSY137L4

IS THE ORPHANAGE FILLING UP? PROJECTING THE GROWTH AND BUDGETIMPACT OF ORPHAN DRUGS IN EUROPE

Flostrand S, Rodriguez I, Maddox B,Finch L, Belulaj S, Gould A

PosterPresentation

PSY145L12

HOW DOES THE ADDITIONAL BENEFIT EXTENT OF ORPHAN DRUGS IMPACTPRICE NEGOTIATIONS IN THE GERMAN OUTPATIENT SECTOR? Schwarz R, Freiberg M Poster

Presentation

PSY157L24

DRIVERS IN HTA DECISION-MAKING FOR CHOLESTEROL LOWERING PCSK9INHIBITORS

Kreeftmeijer J, Dekkers R, van Engen A

PosterPresentation

PSY159L26

EPIDEMIOLOGY OF PATIENTS RECEIVING HEMATOPOIETIC STEM CELL PATIENTSIN BELGIUM Chevalier P, Tsakeu E, Lamotte M Poster

Presentation

PHS24A24

THE BURDEN OF ILLNESS IN PATIENTS WITH CASTRATE-RESISTANT PROSTATECANCER WITH BONE METASTASES IN ASIA PACIFIC (AUSTRALIA, SOUTH KOREA,AND TAIWAN)

Gemmen E, Patil DS PosterPresentation


QuintilesIMS Activities 1 NovemberTU

ESDAY 1


9 | QuintilesIMS at ISPOR, Vienna, 2016


PHS45B7

HOSPITALIZATION COST AND LENGTH OF STAY ASSOCIATED WITH HPV-RELATED DISEASES Tsakeu E, Petit C, Chevalier P Poster

Presentation

PHS95C19

UNDERSTANDING THE ROLE OF DERMATOLOGISTS AND ONCOLOGISTS INMELANOMA TREATMENT IN FRANCE AND THE UK Mpima S, Casey V, Nasuti P Poster

Presentation

PHS99C23

PATIENT CENTRICITY – PATIENT RELATED PROGRAMS IN THE GERMANHEALTHCARE ENVIRONMENT

Schwarz R, Freiberg M, Sprick J,Thiele J

PosterPresentation

PCV3E30

ROSUVASTATIN: SWITCHING TREATMENT AND CLINICAL IMPLICATIONS INPRIMARY CARE Heiman F, Ripellino C, Colivicchi F Poster

Presentation

PCV4E31 HIGH RISK OF DEPRESSION IN PATIENTS WITH HEART FAILURE IN GERMANY Konrad M, Booker A, Kostev K Poster

Presentation

PCV23F12

REAL-WORLD HOSPITALISATION AND MORTALITY OF INCIDENT AND PREVALENT PATIENTS WITH HEART FAILURE DUE TO LEFT VENTRICULARSYSTOLIC DYSFUNCTION IN ENGLAND

Gielen V, Gondos A, Alexopoulos S PosterPresentation

PCV77G28

HISTORICAL AND FUTURE ORAL LIPID MODIFYING THERAPY MARKET SIZE INTOP FIVE EUROPEAN COUNTRIES

Ray KK, Gorcyca K, Iorga Ş, McMahon A

PosterPresentation

PCV114H27

PHARMACOUTILIZATION IN PATIENTS SUFFERING FROM NON-VALVULAR ATRIALFIBRILLATION

Cataldo N, Ripellino C, Di Virgilio R,De Solda F

PosterPresentation

PCV127I2

PREVALENCE OF THERAPY-RESISTANT HYPERCHOLESTEROLEMIA IN HIGH-RISKCARDIOVASCULAR PATIENTS IN GERMANY

Kostev K, Parhofer K, Dombrowski S,Dippel F

PosterPresentation

PDB3I35

THE ROLE OF WEIGHT LOSS OR GAIN IN PAYER ASSESSMENT OF DIABETESDRUGS

Khoury C, Bergenheim K, van Engen A, Hellsten Kronander A

PosterPresentation

PDB4I36

COST OF ANTIHYPERGLYCEMIC THERAPY IN TYPE 2 DIABETES PATIENTSDEPENDING ON HBA1C AND BMI VALUES Sorg A, Dombrowski S, Kostev K Poster

Presentation

PDB7J2

COMBINING A REAL-WORLD OBSERVATIONAL STUDY AND A NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS TO DETERMINERELATIVE TREATMENT EFFECTS IN TYPE 2 DIABETES

Reason T, Hankins M, Lovato E,Pitcher A, Schlueter M, Abrams KR

PosterPresentation

PDB12J7

TREATMENT OUTCOMES FOLLOWING INITIATION OF DAPAGLIFLOZIN OR BASAL SUPPORTED ORAL THERAPY AMONG TYPE 2 DIABETES PATIENTS INPRIMARY CARE PRACTICES IN GERMANY

Ehlken B, Kostev K PosterPresentation

PDB36J31

COST PER RESPONDER OF LIXISENATIDE VERSUS RAPID-ACTING INSULININTENSIFICATION REGIMENS IN AN INSULIN-EXPOSED TYPE 2 DIABETESMELLITUS (T2DM) POPULATION

Afonso M, Ryan F, Pitcher A, Lew E PosterPresentation

PDB54K12

LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITHTYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS

Ramírez de Arellano Serna A,Mezquita-Raya P, Vega-Hernandez G,Wojcik R, Schlueter M

PosterPresentation

PDB56K14

COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THETREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK

Schlueter M, Vega-Hernandez G,Wojcik R

PosterPresentation

PDB57K15

COST-UTILITY EVALUATION OF INSULIN GLARGINE 300 (GLA-300) VERSUSINSULIN GLARGINE 100 (GLA-100) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

Delgado M, Rubio M, Gasche D,Fournier M, Monereo S

PosterPresentation


QuintilesIMS Activities 1 NovemberTU

ESDAY 1



PMD70B32

ASSESSING THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVEIMPLANTATION IN INOPERABLE PATIENTS WITH SEVERE AORTIC STENOSIS IN UK

Ramos M, Lamotte M, Chevalier P,Goodall G

PosterPresentation

PMD74B36

COST EFFECTIVENESS ANALYSIS OF A FLASH GLUCOSE MONITORING SYSTEMFOR TYPE 1 DIABETES (T1DM) PATIENTS RECEIVING INTENSIVE INSULINTREATMENT IN EUROPE AND AUSTRALIA

Bilir SP, Li H, Wehler EA, Hellmund R,Munakata J

PosterPresentation

PMD75B37

COST EFFECTIVENESS ANALYSIS OF A FLASH GLUCOSE MONITORING SYSTEMFOR TYPE 2 DIABETES (T2DM) PATIENTS RECEIVING INTENSIVE INSULINTREATMENT IN EUROPE

Li H, Bilir SP, Wehler EA, Hellmund R,Munakata J

PosterPresentation

PMD106C29 REGIONAL MARKET ACCESS PATHWAYS FOR DIAGNOSTICS IN ITALY Mantuano M, Urbinati D, Daniel F,

Tettamanti APosterPresentation

PCN45E20

IN-HOSPITAL MORTALITY AND COMPLICATIONS FOLLOWING SURGICALRESECTION OF GLIOBLASTOMA Chevalier P, van Gils C, Lamotte M Poster

Presentation

PCN47E22

REAL LIFE PROGRESSION FREE SURVIVAL AND TREATMENT PATTERNS FORPATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITHTARGETED THERAPIES IN FRANCE: ANALYSIS OF IMS RWD ONCOLOGY CROSS-SECTIONAL SURVEY DATA

Maroun R, Mitrofan L, Benjamin L,Nachbaur G, Maunoury F, Le Jeunne P, Durand-Zaleski I

PosterPresentation

PCN82F19 COSTS EVOLUTION OF CANCER THERAPIES IN EUROPE FROM 2004 TO 2014 Tetafort A, Aubert J, Perrot D,

Brigot G, Kolahi C, Ansolabehere XPosterPresentation

PCN99F36 COSTS OF HPV-RELATED CANCERS IN THE NETHERLANDS

Salem A, Pervaiz S, Breeveld-dwarkasing V, Dhont P, Slierendregt B, van Gils CW

PosterPresentation

PCN150H10

USE OF REAL WORLD DATA IN IDENTIFYING RELEVANT COMPARATORS INMEDICO ECONOMIC MODELS AT EU5 LEVEL: A CASE STUDY ON MULTIPLEMYELOMA

Jubert H, Kolahi C, Karusisi N,Mitrofan L

PosterPresentation

PCN182I3

COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN GASTROINTESTINALSTROMAL TUMOURS IN ENGLAND USING CROSSOVER ADJUSTMENT METHODS

Pitcher A, Grabbi E, Madin-Warburton M,Vadgama S

PosterPresentation

PCN233J16

DESCRIPTION OF FIRST-LINE TREATMENTS IN PATIENTS WITH NON-RESECTABLE COLORECTAL CANCERS IN BELGIUM Chevalier P, van Gils C, Lamotte M Poster

Presentation

PCN239J22

WHICH TYPES OF ECONOMIC EVALUATIONS ARE CONSIDERED BY HEALTHTECHNOLOGY ASSESSMENT AGENCIES?

Puig-Peiró R, Roset M, Gilabert Perramon A, Viayna E, Prat A, Gómez-Navarro V

PosterPresentation

PCN240J23

ASSESSMENT OF DECISIONS AND COST-EFFECTIVENESS CRITERIA CONSIDERED BY SEVEN HEALTH TECHNOLOGY ASSESSMENT AGENCIES

Puig-Peiró R, Planellas L, Gilabert Perramon A, Roset M, Barrull C, Prat A, Solozabal M

PosterPresentation

PCN243J26

REAL WORLD DATA: USE OF NOVEL TREATMENTS AND BIOMARKERS INMALIGNANT MELANOMA IN EUROPEAN COUNTRIES

von Bredow D, Kolb N, Bernhardt M,Schmidt N

PosterPresentation

PCN249J32

GENERIC DRUG VOLUME AND COST SAVINGS IN ONCOLOGY: A 2005-2014MIDAS ANALYSIS

Divino V, Coyle K, Kleinrock M, Wade RL, DeKoven M, Kaura S

PosterPresentation

PCN250J33

ASSESSMENT OF CLINICAL VALUE IN ONCOLOGY: COMPARATIVE ANALYSIS OFVALUE FRAMEWORKS AND HTAS

Niven C, Hough NM, Zhou AY, Qin L, Alexander R

PosterPresentation

PCN259K5 LANDSCAPE OF ADVANCED NSCLC: THE IMPACT OF UPCOMING THERAPIES Soares M, Bento MJ,

Rocha-Gonçalves FN, Sousa J, Rigor HPosterPresentation

PCN291K36

HOW DOES HEALTH TECHNOLOGY ASSESSMENT OF PERSONALIZED MEDICINEFOR NON-SMALL CELL LUNG CANCER DIFFER IN FRANCE, GERMANY, ANDENGLAND?

Sherwood A, Mitrofan L PosterPresentation


QuintilesIMS Activities 2 NovemberWED

NES

DAY 2


All functions can derive value by having a shared view of what is happening in real-life healthcare settings.

QuintilesIMS supports stakeholder ambitions to generate the richest real-world insights possible.

Applying the appropriate scientific and commercial lens and latest techniques to anonymous RWD is critical to

realizing the value of real-world evidence in healthcare decisions.

QuintilesIMS can uniquely support all elements of the

RWI Ecosystem - from addressing discrete RWE needs to

building entire data and technology platforms tailored

to specific therapy areas.

Watch your real-world insights grow

Real-World DataIdentify and access the most appropriate data sources while ensuring patient privacy

• The broadest and deepest collection of scientifically-validated, anonymous patient-level data assets complemented by custom data sourcing

Technology-Enabled AnalyticsLeverage groundbreaking technology and applications to enable consistent RWI globally

• Extraction, analysis and visualization of RWD with the QuintilesIMS E360TM technology suite • Sophisticated data linkage and interpretation• Study-specific electronic data capture (EDC)

Services and EngagementDesign, create and deploy RWI that drives decision making and alignment

• Market Access & HTA• Health Economics• Outcomes Research• Pharmacoepidemiology

& Drug Safety • Commercial Analytics


HOLISTIC APPROACH TO REAL-WORLDINSIGHTS

QuintilesIMS Our Distinctive Approach


QuintilesIMS Real-World Insights Bibliography

Our research expertise and market knowledge, spanning clinical

to commercial to real-world insights, are captured in more than

4,200 publications. Spanning virtually all therapeutic areas,

these reflect original analyses and projects completed in over

50 countries worldwide.

Pick up a copy of our latest

compilation of published papers and

presentations (2014-2016) from our

Stand at ISPOR or visit

www.rwebibliography.com

to explore our full database online.

Real-World InsightsVisit us at www.quintilesims.com or email [email protected]

Copyright © 2016 QuintilesIMS. All rights reserved. 13.0024-1-10.16_QI The IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 names and logos, as well as any otherQuintilesIMS service or product names or logos are the registered trademarks or trademarks of QuintilesIMS.

572

562

554

226

205

221

148130

Oncology/Hematology

Cardiovascular

Diabetes

Mental Health

Respiratory Disease

Neurological Disorders

Infectious Diseases

Gastrointestinal

2,600+publications in

key therapy areas


join us at ispor vienna - iqvia · qi ispor vienna invite orb1679_layout 1 17/10/2016 06:32 page 2...

Documents